Beijing Kawei Biopharmaceutical Technology

Beijing Kawei Biopharmaceutical Technology is a Chinese biotechnology company primarily focused on the development and commercialization of therapeutic monoclonal antibodies for oncology. The company is best known for its pivotal role in establishing Biotech Pharma Co., Ltd., a high-profile joint venture between China and Cuba. Its flagship product, Nimotuzumab (brand name Taixinsheng), is a humanized anti-EGFR monoclonal antibody approved in China for the treatment of nasopharyngeal carcinoma and other solid tumors. Beijing Kawei continues to support the clinical expansion of its oncology portfolio through various stages of development. The company maintains a strong focus on biologics manufacturing and international R&D collaborations.